A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)

Recruiting

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(18 sites)

United States

University of California, San Diego - Altman Clinical and Translational Research Institute (ACTRI), La Jolla, California

Samir Macwan, M.D., Inc. (S corporation), Rancho Mirage, California

EZR Research, Boca Raton, Florida

University of Florida Jacksonville, Jacksonville, Florida

Visionary Investigators Network, Miami, Florida

University of California Irvine, Orange, Florida

Medsol Clinical Research Center Inc, Port Charlotte, Florida

Baycare Medical Group, St. Petersburg, Florida

Emory Brain Health Center, Atlanta, Georgia

The Queen's Medical Center - West Oahu, Honolulu, Hawaii

Hawaii Pacific Neuroscience, Honolulu, Hawaii

HSHS Medical Group, O'Fallon, Illinois

UMass Memorial Medical Center, Worcester, Massachusetts

Henry Ford Health System, Detroit, Michigan

Cleveland Clinic, Cleveland, Ohio

Erlanger Neuroscience Institute, Chattanooga, Tennessee

Central Texas Neurology Consultants - Elligo, Round Rock, Texas

Center for Neurological Disorders - Greenfield, Greenfield, Wisconsin